Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Similar articles for PubMed (Select 24285762)

1.

An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors.

Makkar KM, Sanoski CA, Goldberg LR, Spinler SA.

Ann Pharmacother. 2013 Nov;47(11):1457-62. doi: 10.1177/1060028013504077.

PMID:
24285762
2.
3.

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.

Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.

4.

Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.

Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM.

Liver Transpl. 2009 May;15(5):504-8. doi: 10.1002/lt.21710.

5.

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.

Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group.

Am Heart J. 2004 Sep;148(3):447-55.

PMID:
15389231
6.

The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.

Crespo-Leiro MG, Paniagua MJ, Marzoa R, Grille Z, Naya C, Flores X, Rodriguez JA, Mosquera V, Franco R, Castro-Beiras A.

Transplant Proc. 2008 Nov;40(9):3060-2. doi: 10.1016/j.transproceed.2008.09.007.

PMID:
19010194
9.

Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy.

Le VV, Racine N, Pelletier GB, Carrier M, Cossette M, White M.

Clin Transplant. 2009 Mar-Apr;23(2):249-55.

PMID:
19402219
10.

Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.

Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA; Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators.

Am J Cardiol. 2009 Sep 15;104(6):798-804. doi: 10.1016/j.amjcard.2009.05.019. Epub 2009 Jul 23.

PMID:
19733714
11.

Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.

Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.

Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013.

PMID:
18343245
12.
13.

The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia.

Hiramitsu S, Ishiguro Y, Matsuyama H, Yamada K, Kato K, Noba M, Uemura A, Yoshida S, Matsubara Y, Kani A, Hasegawa K, Hishida H, Ozaki Y.

J Atheroscler Thromb. 2010 Feb;17(1):106-14. Epub 2010 Jan 14.

14.

Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.

González CA, Rubio-Guerra AF, Pavía A, Redding FJ, Cervantes JL, Zacarías JL, Yza R, Carranza J, Fernández P, Morales E, Robles FJ, Leyva JL, Rodríguez L.

Clin Drug Investig. 2007;27(5):333-7.

PMID:
17451281
15.

The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients.

Yoon HE, Song JC, Hyoung BJ, Hwang HS, Lee SY, Jeon YJ, Choi BS, Kim YS, Yang CW.

Korean J Intern Med. 2009 Sep;24(3):233-7. doi: 10.3904/kjim.2009.24.3.233. Epub 2009 Aug 26.

17.

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.

Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B.

Curr Med Res Opin. 2004 Sep;20(9):1437-45.

PMID:
15383192
18.

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

Meyers CD, Moon YS, Ghanem H, Wong ND.

Ann Pharmacother. 2006 May;40(5):818-23. Epub 2006 Apr 25.

PMID:
16638916
19.
20.

Ezetimibe in heart transplantation: initial experience.

Moro J, Almenar L, Martínez-Dolz L, Izquierdo M, Agüero J, Sánchez-Lazaro I, Ortiz V, Salvador A.

Transplant Proc. 2007 Sep;39(7):2389-92.

PMID:
17889199
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk